Patents Assigned to Glaxo Group Limited
  • Method of Determining Cleanliness
    Publication number: 20130213154
    Abstract: A method of determining cleanliness of a manufacturing area is disclosed. The method of determining cleanliness of a manufacturing area comprising swabbing at least one target area within the manufacturing area, placing the swab in a testing apparatus, analyzing for the presence of the at least one substance with the testing apparatus and determining in real time the cleanliness of the manufacturing area.
    Type: Application
    Filed: November 9, 2011
    Publication date: August 22, 2013
    Applicant: GLAXO GROUP LIMITED
    Inventors: Timothy M. Crowder, Jason E. Dickens, Kevin J. Ely, Dwight Sherod Walker
  • Dispensing Device
    Publication number: 20130213394
    Abstract: A dust cap for a pMDI having a cap part adapted for a push-fit on the dispensing nozzle of the pMDI and a strap part for connecting the dust cap to the pMDI, wherein the cap part is slidably mounted on the strap part for sliding movement between an extended position and a contracted position.
    Type: Application
    Filed: March 18, 2013
    Publication date: August 22, 2013
    Applicant: Glaxo Group Limited
    Inventors: Gregor John McLennan Anderson, Allen John Pearson, Peter John Brand, Mark Anthony Cox, Ian Cude, Philip William Farr, Andrew Michael Kelly, Daniel Thomas de Sausmarez Lintell, Paul Kenneth Rand
  • Medicament dispenser
    Patent number: 8511304
    Abstract: There is provided a medicament dispenser for use with plural elongate form medicament carriers, each having multiple distinct medicament dose portions carried thereby, the dispenser having a dispensing mechanism for dispensing the distinct medicament dose portions carried by each of the plural medicament carriers. The mechanism comprises a receiving station for receiving each of the plural medicament carriers; a release for releasing a distinct medicament dose portion from each of the plural medicament carriers on receipt thereof by the receiving station; an outlet, positioned to be in communication with the distinct medicament dose portions releasable by said a release; and an indexer for individually indexing the distinct medicament dose portions of each of the plural medicament carriers.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: August 20, 2013
    Assignee: Glaxo Group Limited
    Inventors: Gregor John McLennan Anderson, Stanley George Bonney, Michael Birsha Davies, Daniel Thomas De Sansmarez Lintell, Alan Anthony Wilson
  • 5,6,7,8-tetrahydroimidazo[1,2-A]pyrazine derivatives as P2X7 modulators
    Patent number: 8513248
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis or osteoarthritis or neurodegenerative disorders.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: August 20, 2013
    Assignee: Glaxo Group Limited
    Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Ian David Wall, Daryl Simon Walter
  • Method of Treatment
    Publication number: 20130210892
    Abstract: A method of treating autoimmune and inflammatory diseases or conditions in a mammal, such as a human, which comprises the administration of a inhibitor of the bromodomain-containing protein: SP110
    Type: Application
    Filed: October 25, 2011
    Publication date: August 15, 2013
    Applicant: Glaxo Group Limited
    Inventors: Kevin Lee, David Francis Tough
  • Compounds
    Patent number: 8507543
    Abstract: Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: August 13, 2013
    Assignee: Glaxo Group Limited
    Inventors: Simon Teanby Hodgson, Yannick Maurice Lacroix, Panayiotis Alexandrou Procopiou
  • 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS
    Publication number: 20130203802
    Abstract: A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR5; or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and C1-2alkyl; R2 is selected from H, C1-2alkyl, OH, —CH2OH and C1-2alkoxy; Each R3 is independently selected from OH, C1-3alkyl, F, Cl, Br, NH2, and C1-3alkoxy; R4 is selected from C1-3alkyl and haloC1-3alkyl; R5 is selected from H, C1-3alkyl and haloC1-3alkyl; R6 and R7 are either i) each independently selected from H, C1-3alkyl and C1-3alkoxy; or ii) R6 and R7 together with the ring to which they are attached form a 9-membered bicyclic ring; p is 0-3; and RA is selected from H and C1-3alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.
    Type: Application
    Filed: October 11, 2011
    Publication date: August 8, 2013
    Applicant: GLAXO GROUP LIMITED
    Inventors: Julia Castro Pichel, Raquel Fernandez Menendez, Esther Pilar Fernandez Velando, Silvia Gonzalez Del Valle, Araceli Mallo-Rubio
  • Pyrazole Compounds Acting Against Allergic, Immune and Inflammatory Conditions
    Publication number: 20130203705
    Abstract: The present invention relates to a pyrazole amide derivative, pharmaceutical compositions containing this compound and to its use in therapy.
    Type: Application
    Filed: October 19, 2011
    Publication date: August 8, 2013
    Applicant: Glaxo Group Limited
    Inventors: Anthony William James Cooper, Paul Martin Gore, David House
  • 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators
    Patent number: 8501946
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: August 6, 2013
    Assignee: Glaxo Group Limited
    Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Daryl Simon Walter
  • MAGI POLYNUCLEOTIDES, POLYPETIDES, AND ANTIBODIES
    Publication number: 20130196412
    Abstract: MAGI polypeptides, polynucleotides, antibodies, and methods for producing the same by recombinant techniques are disclosed. Also disclosed are methods for utilizing MAGI polypeptides and polynucleotides in diagnostic assays.
    Type: Application
    Filed: March 18, 2013
    Publication date: August 1, 2013
    Applicant: Glaxo Group Limited
    Inventor: Glaxo Group Limited
  • FUSIONS AND CONJUGATES OF INSULINOTROPIC AGENTS
    Publication number: 20130189255
    Abstract: The present invention relates to drug fusions of insulinotropic agents and incretin drugs that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.
    Type: Application
    Filed: January 17, 2013
    Publication date: July 25, 2013
    Applicant: GLAXO GROUP LIMITED
    Inventor: GLAXO GROUP LIMITED
  • Sanitizing formulation
    Patent number: 8491878
    Abstract: A sanitizing formulation comprising a solution of an acidic polymer and an anionic surfactant in a liquid vehicle. Suitable acidic polymers are those which include adjacent —[—CR1.COOH—]— units where R1 is defined in their structure, for example polymers based on maleic acid moieties which typically include —[—CH.COOH—CH.COOH—]— units, such as known Gantrez™ polymers. A suitable anionic surfact is sodium lauryl sulphate.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: July 23, 2013
    Assignee: Glaxo Group Limited
    Inventors: Simon King, Madhu Parmar, Kimberly Biedermann, Philip Oths
  • 1-benzoyl substituted diazepine derivatives as selective histamine H3 receptor agonists
    Patent number: 8492375
    Abstract: The present invention relates to novel diazepanyl derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: July 23, 2013
    Assignee: Glaxo Group Limited
    Inventors: Gordon Bruton, Anthony Huxley, Barry Sidney Orlek, Kishore Kalidas Rana
  • 1,2-diphenylethene derivatives for treatment of immune diseases
    Patent number: 8487009
    Abstract: The invention provides novel 1,2-diphenylethene derivatives and pharmaceutically acceptable salts thereof, the process for production of these compounds and their pharmaceutical composition and the use of these compounds as modulators of T-cells, neutrophils, macrophages and their associated cytokines as agents for treating immune, inflammatory and auto-immune diseases.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: July 16, 2013
    Assignee: Glaxo Group Limited
    Inventors: Genhui Chen, John M. Webster, Jianxiong Li, Wei Liu
  • Compounds which have activity at M1 receptor and their uses in medicine
    Patent number: 8481566
    Abstract: Compounds of formula (I) and salts and solvates are provided: wherein R4 is fluoro, R5 is selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6alkoxy, and C1-6alkoxy substituted with one or more fluorine atoms; and R6 is selected from halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6alkoxy and C1-6alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C1-6alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: July 9, 2013
    Assignee: Glaxo Group Limited
    Inventors: Brian Budzik, David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Dongchuan Shi, Graham Walker
  • Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
    Patent number: 8470835
    Abstract: The present invention relates to the compound of formula (I): or a salt, preferably a pharmaceutically acceptable salt, thereof; is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate mast cell activation, for instance allergic and inflammatory diseases, as well of potential use in cancer therapy, specifically heme malignancies.
    Type: Grant
    Filed: January 11, 2010
    Date of Patent: June 25, 2013
    Assignee: Glaxo Group Limited
    Inventors: Francis Louis Atkinson, Vipulkumar Kantibhai Patel
  • SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS
    Publication number: 20130131338
    Abstract: A method of treating or preventing diseases or conditions mediated through the action of oxytocin which comprises administering to a human in need thereof of an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 14, 2012
    Publication date: May 23, 2013
    Applicant: Glaxo Group Limited
    Inventor: Glaxo Group Limited
  • MACHINE AND METHOD FOR PHARMACEUTICAL AND PHARMACEUTICAL-LIKE PRODUCT ASSEMBLY
    Publication number: 20130118132
    Abstract: A method and apparatus for assembling a plurality of independently formed solid components is provided thereby forming a single delivery vehicle for a pharmaceutical or pharmaceutical-like product. The solid components can be held and fed to the apparatus via a plurality of magazines. Pusher rods and the like can be used for positioning each of the solid components. Where the components are connected via a bonding liquid, a sprayer is provided and compression pins or the like press the components with the bonding liquid together to form the final project. A rivet or other connection structure can also be used and driven through holes in each of the solid components to form the final product.
    Type: Application
    Filed: January 10, 2013
    Publication date: May 16, 2013
    Applicant: Glaxo Group Limited
    Inventors: Thomas Bailey, Ronnie Benditt, Brewerton Nigel, Steven D. Finkelmeier, Robert Glinecke, Martini Luigi, Paul Simmons
  • NOVEL CRYSTALLINE FORMS OF (3R, 6R)-3-(2,3-DIHYDRO-1H-INDEN-2-YL)-1-[(1R)-1-(2,6-DIMETHYL-3-PYRIDINYL)-2-(4-MORPHOLINYL)-2-OXOETHYL]-6-[(1S)-1-METHYLPROPYL]-2,5-PIPERAZINEDIONE
    Publication number: 20130109690
    Abstract: The present invention relates to crystalline forms of (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione benzenesulfonate salt and pharmaceutical compositions thereof. Also disclosed are processes for the preparation the above compounds and methods for use thereof.
    Type: Application
    Filed: October 28, 2010
    Publication date: May 2, 2013
    Applicant: GLAXO GROUP LIMITED
    Inventors: Richard Bellingham, Andrew Mark Buswell, Victoria Mary Ironmonger, Michael Urquhart
  • Spiroindolines as modulators of chemokine receptors
    Patent number: 8431590
    Abstract: The present invention relates to a compound of the following formula: where R1-R6, R10, Y, n, m, p, and q are as defined herein. Compounds and compositions of the present invention are useful for the treatment of diseases associated with the overexpression of CCR2.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: April 30, 2013
    Assignee: Glaxo Group Limited
    Inventors: Brian W. Budzik, Hilary Schenck Eidam, Ryan Michael Fox, Krista B. Goodman, Dimitar B. Gotchev, Pamela A. Haile, Terry Vincent Hughes, Ronggang Liu, Nathan A. Miller, Tamara Ann Miskowski, Clark A. Sehon, Andrew Q. Viet, Gren Z. Wang, Jing Zhang